Although it may sound almost unrealistic, a small team of Israeli scientists have just announced that they are close to completing the first cancer medication in just one year and claiming to be short, inexpensive and above all, completely effective.
And according to the World Health Organization (WHO), the global cancer burden is estimated to increase to 18.1 million new cases, which affects 1 in 5 men and 1 in 6 women worldwide, and reaching 9.6 million deaths during the past 2018.
"We believe in that we will offer one year full remedy for cancer"Said Dan Aridor, chairman of the board of accelerated evolution of biotechnology (AEBi),"It will be effective from the first day, it will last for several weeks, and there will be minimal side effects or none, at a much lower price than most other treatments on the market"
Denominated MuTaTo (multi-purpose toxin), this drug is essentially defined as an "antibiotic" for cancer, using it a combination of peptides directed to the disease, and a toxin that will specifically kill cancer cells.
Thus, while trying to create a general drug, the treatment of cancer through Mutato It will be specially designed for every person, analysis of the samples from each biopsy to know which receptors are too big.
In this way, under the leadership of Ilan Murad, CEO of AEB, this breakthrough is still in the development stage dedicated to the discovery and development of new therapeutic peptides that provide a solid path to these difficult targets, which represent several advantages over the antibodies, are smaller, cheaper and easier to produce and regulate.
Morad compared the MuTaTo concept with a triple drug cocktail that helped change AIDS from automatic death penalty, of chronic disease. But, unlike HIV and AIDS, where patients must take medication forever, with Mutato, cells will be killed, so you can stop treatment in just a few weeks.
Although they claim that next year this remedy will be completed, by the time the company is limited to In vitro tests and experimental mice experiments, which show the inhibition of the growth of human cancer cells without showing any effect on healthy cells.
AEBi has already confirmed that it will soon begin with the first rounds clinical trials with people.